| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Phenylacetate, an inducer of tumor cytostasis and differentiation, shows promise as a relatively nontoxic antineoplastic agent. Phenylacetate, however, has an unpleasant odor that might limit patient acceptability. Phenylbutyrate, an odorless compound that also has activity in tumor models, is known to undergo rapid conversion to phenylacetate by beta-oxidation in vivo. This phase I study examined the pharmacokinetics of phenylbutyrate and characterized the disposition of the two metabolites, phenylacetate and phenylacetylglutamine. Fourteen patients with cancer (aged 51.8 +/- 13.8 years) received a 30-minute infusion of phenylbutyrate at 3 dose levels (600, 1200, and 2000 mg/m2). Serial blood samples and 24-hour urine collections were obtained. Samples were assayed by high-performance liquid chromatography. A model to simultaneously describe the pharmacokinetics of all three compounds was developed using ADAPT II. Data were modeled as molar equivalents. The model fit the data well as shown by mean (+/- SD) coefficients of determination (r2) for phenylbutyrate, phenylacetate, and phenylacetylglutamine, which were 0.96 +/- 0.07, 0.88 +/- 0.10, and 0.92 +/- 0.06, respectively. The intrapatient coefficient of variation percentage (CV%) around the parameter estimates were small (range 7.2-33.5%). Phenylbutyrate achieved peak concentrations in the range of in vitro tumor activity (500-2000 mumol/L) and exhibited saturable elimination (Km = 34.1 +/- 18.1 micrograms/mL and Vmax = 18.1 +/- 18 mg/h/kg). Metabolism was rapid; the times to maximum concentration for phenylacetate and phenylacetylglutamine were 1 and 2 hours, respectively. The conversion of phenylbutyrate to phenylacetate was extensive (80 +/- 12.6%), but serum concentrations of phenylacetate were low owing to rapid, subsequent conversion to phenylacetylglutamine.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-N. Li, S. Parikh, Q. Shu, H.-L. Jung, C.-W. Chow, L. Perlaky, H.-C. E. Leung, J. Su, S. Blaney, and C. C. Lau Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells Clin. Cancer Res., February 1, 2004; 10(3): 1150 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kasumov, L. L. Brunengraber, B. Comte, M. A. Puchowicz, K. Jobbins, K. Thomas, F. David, R. Kinman, S. Wehrli, W. Dahms, et al. NEW SECONDARY METABOLITES OF PHENYLBUTYRATE IN HUMANS AND RATS Drug Metab. Dispos., January 1, 2004; 32(1): 10 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Gore, L.-J. Weng, W. D. Figg, S. Zhai, R. C. Donehower, G. Dover, M. R. Grever, C. Griffin, L. B. Grochow, A. Hawkins, et al. Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia Clin. Cancer Res., April 1, 2002; 8(4): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Carducci, J. Gilbert, M. K. Bowling, D. Noe, M. A. Eisenberger, V. Sinibaldi, Y. Zabelina, T.-l. Chen, L. B. Grochow, and R. C. Donehower A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule Clin. Cancer Res., October 1, 2001; 7(10): 3047 - 3055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Gore, L.-J. Weng, S. Zhai, W. D. Figg, R. C. Donehower, G. J. Dover, M. Grever, C. A. Griffin, L. B. Grochow, E. K. Rowinsky, et al. Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia Clin. Cancer Res., August 1, 2001; 7(8): 2330 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Chung, Y.-H. W. Lee, S.-H. Yen, and K.-H. Chi A Novel Approach for Nasopharyngeal Carcinoma Treatment Uses Phenylbutyrate as a Protein Kinase C Modulator: Implications for Radiosensitization and EBV-targeted Therapy Clin. Cancer Res., April 1, 2000; 6(4): 1452 - 1458. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Yang and H. Brunengraber Glutamate, a Window on Liver Intermediary Metabolism J. Nutr., April 1, 2000; 130(4): 991 - 991. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Witt, K. Sand, and A. Pekrun Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways Blood, April 1, 2000; 95(7): 2391 - 2396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Witzig, M. Timm, M. Stenson, P. A. Svingen, and S. H. Kaufmann Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents Clin. Cancer Res., February 1, 2000; 6(2): 681 - 692. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Chang, J. G. Kuhn, H. I. Robins, S. C. Schold, A. M. Spence, M. S. Berger, M. P. Mehta, M. E. Bozik, I. Pollack, D. Schiff, et al. Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report J. Clin. Oncol., March 1, 1999; 17(3): 984 - 984. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
